Mifepristone Plus Misoprostol Versus Misoprostol Alone for 2nd Trimester Abortion (14 - 21 Weeks Last Menstrual Period (LMP))
Launched by GYNUITY HEALTH PROJECTS · Sep 1, 2009
Trial Information
Current as of June 09, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 14 to 21 weeks gestation, based on menstrual history and clinical exam (with or without ultrasound)
- • Meet legal criteria to obtain abortion
- • Present with closed cervical os and no vaginal bleeding
- • Live fetus at time of presentation for service
- • Have no contraindications to study procedures, according to provider
- • Be able to consent to procedure, either by reading consent document or by having consent document read to her
- • Be willing to follow study procedures
- Exclusion Criteria:
- • Known previous transmural uterine incision
- • Known allergy to mifepristone or misoprostol/prostaglandin or other contraindications to the use of mifepristone or misoprostol
- • Any contraindications to vaginal delivery, including placenta previa
- • Presentation in active labor (defined as moderate to severe contractions every 10 minutes or less)
About Gynuity Health Projects
Gynuity Health Projects is a clinical trial sponsor dedicated to advancing reproductive health through innovative research and development. Focused on improving access to safe and effective contraceptive methods and reproductive healthcare services, Gynuity collaborates with healthcare providers, researchers, and policymakers to conduct rigorous clinical trials. With an emphasis on evidence-based practices, the organization aims to inform and enhance reproductive health policies globally, ensuring that women and communities benefit from the latest advancements in healthcare. Their commitment to ethical standards and patient-centered research underscores their role as a leader in the field of reproductive health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chishinau, , Moldova, Republic Of
Tunis, , Tunisia
Patients applied
Trial Officials
Beverly Winikoff
Principal Investigator
Gynuity Health Projects
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials